Clinical and pharmacokinetic evaluation of moxalactam in infants and children.
Moxalactam, a new beta-lactam antibiotic was evaluated in the treatment of 21 pediatric patients including 16 with clinical and radiological evidence of pneumonia and 5 with urinary tract infection (UTI). Clinical and radiological resolution of pneumonia occurred in all. Bacteriological efficacy in pneumonia, however, was assessed in only 1 patient whose blood culture grew H. influenzae type b. In patients with UTI, the therapy was successful, bacteriologically as well as clinically. The only side effects observed were mild transient elevation of SGOT and alkaline phosphatase in 6 cases. The peak and trough levels of the drug were manyfold higher than the known minimum inhibitory concentrations of common pathogens. The mean t1/2 projected of 95 and 124 min with intravenous and intramuscular route, respectively, were similar to those reported in adults.
D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy / Q000378:metabolism*; D002511:Cephalosporins / Q000378:metabolism*; D002513:Cephamycins / Q000378:metabolism* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007677:Kidney Function Tests; D007700:Kinetics; D008111:Liver Function Tests; D008297:Male; D009070:Moxalactam; D011014:Pneumonia / Q000188:drug therapy / Q000378:metabolism*; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000378:metabolism*
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam